Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study
We commend Zanjani et al.1 for an excellent study comparing tacrolimus and interferon alpha-2b (IFN alpha-2b) eye drops in the treatment of vernal keratoconjunctivitis. However, a few untouched and warranted issues need further discussion. First, although the total number of patients recruited has been stated, no mention has been made of the number of patients in each group in the entire article. There is a discrepancy in the total percentage of male patients. The abstract mentions, “Thirty-one patients (77.5%) were male”; however, the Results section states, “In the tacrolimus and interferon groups, 51.6% and 48.4% were male, respectively.” Second, what was the dosage frequency of tacrolimus and interferon drops in each group? Third, exclusion criteria should include contact lens users, as their use might predispose to increased signs and symptoms. Moreover, patients with a history of herpes simplex dendritic keratitis should also be excluded because it may reactivate because of immunosuppressive properties of tacrolimus.